Ozempic now available in India

 Ozempic, the original GLP-1 RA (semaglutide) therapy, researched and developed by Novo Nordisk is now available in India as 0.25 mg, 0.5 mg and 1 mg in FlexTouch Pen.

Weekly pricing of Ozempic is 0.25mg for ₹2,200, 0.5mg for ₹2,542 and 1mg for ₹2,794.

Ozempic, a once-weekly injectable formulation of semaglutide—is approved in India for adults with type 2 diabetes as the first line treatment, adjunct to diet and exercise.

In it release issued on Friday the Company said that the Semaglutide was recently included in WHO’s Model List of Essential Medicines - highlighting the proven health benefits of this innovative treatment for people living with diabetes.

According to the World Health Organisation’s 2023-24 estimates, India has 101 million (roughly 11.4 % of India’s population) people living with diabetes , making it the second largest diabetes-affected populations in the world after China. 

The country also has 136 million individuals with prediabetes and 254 million people living with generalised obesity, signalling an accelerating health challenge that requires effective, evidence-based therapies. 

“Bringing Ozempic to India is a major milestone” said Vikrant Shrotriya - Managing Director, Novo Nordisk India. “Backed by proven clinical excellence & world class quality, reinforced by a robust supply chain, Ozempic offers Indian doctors an effective treatment choice. Our goal is to provide patients an innovative and accessible therapy that offers improved glycaemic control, meaningful weight management and long-term heart and kidney protection – all delivered through a simple, easy-to-use pen device. This once-weekly treatment demonstrates Novo Nordisk’s ongoing commitment to better health outcomes and chronic disease care,” he added.